Abstract
Paclitaxel conjugates of 7-phenylacetamidocephalosporanic acid were prepared as prodrugs for site specific activation by targeted beta-lactamase. Immunologically specific activation of the prodrug 5 containing 3,3-dimethyl-4-amino-butyric acid as linker in combination with the fusion protein L-49-sFv-beta-lactamase was demonstrated in vitro on 3677 melanoma cells.
MeSH terms
-
Antineoplastic Agents, Phytogenic / chemical synthesis*
-
Antineoplastic Agents, Phytogenic / pharmacology*
-
Cephalosporins / chemical synthesis*
-
Cephalosporins / pharmacology*
-
Chromatography, High Pressure Liquid
-
Cyclization
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / pharmacology*
-
Half-Life
-
Humans
-
Immunoglobulin G / pharmacology*
-
In Vitro Techniques
-
Indicators and Reagents
-
Melanoma, Experimental / drug therapy
-
Paclitaxel / analogs & derivatives
-
Paclitaxel / chemical synthesis*
-
Paclitaxel / pharmacology*
-
Prodrugs / chemical synthesis*
-
Prodrugs / pharmacology*
-
Recombinant Fusion Proteins / chemical synthesis*
-
Recombinant Fusion Proteins / pharmacology*
-
Structure-Activity Relationship
-
Tumor Cells, Cultured
-
beta-Lactamase Inhibitors*
-
beta-Lactamases / pharmacology*
Substances
-
Antineoplastic Agents, Phytogenic
-
Cephalosporins
-
Enzyme Inhibitors
-
Immunoglobulin G
-
Indicators and Reagents
-
Prodrugs
-
Recombinant Fusion Proteins
-
beta-Lactamase Inhibitors
-
L49-sFv-beta-lactamase
-
beta-Lactamases
-
Paclitaxel